Nilotinib effective in imatinib-resistant/intolerant CML

    loading  Checking for direct PDF access through Ovid

Abstract

Nilotinib [Tasigna] is associated with major cytogenetic and haematological responses in patients with imatinib [Glivec, Gleevac] -resistant or intolerant chronic myeloid leukaemia (CML) in chronic phase or accelerated phase, according to data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) [Orlando, Florida, US; December 2006]. In patients with imatinib resistant or intolerant CML in chronic phase, nilotinib therapy resulted in approximately 50% of patients experiencing a major cytogenetic response while more than 70% had a complete haematological response after 6 months' follow-up. For patients with similar disease in accelerated phase, haematological response was obtained in almost 60% of nilotinib recipients with 36% of patients achieving a major cytogenetic response. Additional data presented at ASH showed that nilotinib is also effective in patients who have failed prior treatment with two tyrosine kinase inhibitors, namely imatinib and dasatinib.

Related Topics

    loading  Loading Related Articles